Sai Life Sciences Ltd

Sai Life Sciences Ltd

₹ 722 -2.49%
22 May - close price
About

Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]

Key Points

Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.

  • Market Cap 15,050 Cr.
  • Current Price 722
  • High / Low 809 / 635
  • Stock P/E 88.5
  • Book Value 102
  • Dividend Yield 0.00 %
  • ROCE 13.9 %
  • ROE 11.0 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company's working capital requirements have reduced from 138 days to 107 days

Cons

  • Stock is trading at 7.07 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 7.82% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Sep 2024 Dec 2024 Mar 2025
384 439 396 440 580
287 315 293 320 422
Operating Profit 96 125 102 120 158
OPM % 25% 28% 26% 27% 27%
11 3 10 9 10
Interest 23 21 21 23 11
Depreciation 31 31 36 34 37
Profit before tax 53 76 55 72 119
Tax % 25% 26% 25% 25% 26%
40 56 42 54 88
EPS in Rs 2.59 4.24
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
695 760 870 1,217 1,465 1,695
520 593 743 1,048 1,178 1,289
Operating Profit 176 167 126 169 287 406
OPM % 25% 22% 15% 14% 20% 24%
6 27 28 27 29 37
Interest 24 33 54 81 88 76
Depreciation 44 80 90 99 119 139
Profit before tax 113 82 10 16 109 228
Tax % 35% 25% 36% 39% 24% 25%
73 61 6 10 83 170
EPS in Rs 8.16
Dividend Payout % 0% 0% 1,117% 676% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 25%
TTM: 16%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 229%
TTM: 105%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 8%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 16 17 18 18 18 21
Reserves 703 845 861 870 957 2,108
249 637 752 933 929 352
247 318 527 358 359 679
Total Liabilities 1,215 1,817 2,157 2,179 2,262 3,160
373 701 751 1,037 1,180 1,488
CWIP 116 246 410 151 107 124
Investments 0 0 0 2 2 2
726 870 997 989 973 1,545
Total Assets 1,215 1,817 2,157 2,179 2,262 3,160

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
129 -36 105 219 263 314
-158 -260 -102 -99 -191 -537
268 296 72 -201 -95 301
Net Cash Flow 239 -1 75 -80 -24 79

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 123 99 102 85 64 76
Inventory Days 86 127 179 121 72 93
Days Payable 207 230 279 180 163 253
Cash Conversion Cycle 1 -4 2 25 -28 -83
Working Capital Days 133 249 233 178 130 107
ROCE % 3% 6% 11% 14%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2024Mar 2025
35.23% 35.16%
11.72% 12.36%
11.95% 13.26%
41.08% 39.21%
No. of Shareholders 1,81,1221,40,677

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents